Van Lanschot Kempen Logo
  • Home
  • Solutions
  • News & knowledge
  • About us
May 2017
argenx
Issuer's adviser
USD 115 million
Initial public offering on NASDAQ

argenx

argenx is a clinical stage biopharmaceutical company creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases

  • Kempen & Co acted as adviser to the issuer in this transaction

Fully focused on your future

Private Banking

  • Offices
  • Business professionals
  • Executives
  • Doctors
  • Entrepreneurs
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions


Investment Management


Investment Banking



© Van Lanschot Kempen 2022
Security
Privacy & cookies
Disclaimer